Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era

Sanjal H. Desai, Michael A. Spinner, Andrew M. Evens, Alice Sykorova, Veronika Bachanova, Gaurav Goyal, Brad Kahl, Kathleen Dorritie, Jacues Azzi, Vaishalee P. Kenkre, Cheryl Chang, Jozef Michalka, Stephen M. Ansell, Brendon Fusco, Nuttavut Sumransub, Haris Hatic, Raya Saba, Uroosa Ibrahim, Elyse I. Harris, Harsh ShahNina Wagner-Johnston, Sally Arai, Grzegorz S. Nowakowski, Heidi Mocikova, Deepa Jagadeesh, Kristie A. Blum, Catherine Diefenbach, Siddharth Iyengar, K. C. Rappazzo, Firas Baidoun, Yun Choi, Vit Prochazka, Ranjana H. Advani, Ivana Micallef

Research output: Contribution to journalArticlepeer-review

Abstract

In the pre–novel agent era, the median postprogression overall survival (PPS) of patients with classic Hodgkin lymphoma (cHL) who progress after autologous stem cell transplant (ASCT) was 2 to 3 years. Recently, checkpoint inhibitors (CPI) and brentuximab vedotin (BV) have improved the depth and durability of response in this population. Here, we report the estimate of PPS in patients with relapsed cHL after ASCT in the era of CPI and BV. In this multicenter retrospective study of 15 participating institutions, adult patients with relapsed cHL after ASCT were included. Study objective was postprogression overall survival (PPS), defined as the time from posttransplant progression to death or last follow-up. Of 1158 patients who underwent ASCT, 367 had progressive disease. Median age was 34 years (range, 27-46) and 192 were male. Median PPS was 114.57 months (95% confidence interval [CI], 91-not achieved) or 9.5 years. In multivariate analysis, increasing age, progression within 6 months, and pre-ASCT positive positron emission tomography scan were associated with inferior PPS. When adjusted for these features, patients who received CPI, but not BV, as first treatment for post-ASCT progression had significantly higher PPS than the no CPI/no BV group (hazard ratio, 3.5; 95% CI, 1.6-7.8; P = .001). Receipt of allogeneic SCT (Allo-SCT) did not improve PPS. In the era of novel agents, progressive cHL after ASCT had long survival that compares favorably with previous reports. Patients who receive CPI as first treatment for progression had higher PPS. Receipt to Allo-SCT was not associated with PPS in this population.

Original languageEnglish
Pages (from-to)7295-7303
Number of pages9
JournalBlood Advances
Volume7
Issue number23
DOIs
StatePublished - Dec 12 2023

Fingerprint

Dive into the research topics of 'Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era'. Together they form a unique fingerprint.

Cite this